Prothena price target raised to $30 from $20 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Prothena (PRTA) to $30 from $20 and keeps a Buy rating on the shares. The firm believes the market is overlooking the company’s two partnered Phase 3 programs and a partnered Phase 2 asset with blockbuster potential.